Solid Biosciences (SLDB) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

SLDB Stock Forecast

Solid Biosciences stock forecast is as follows: an average price target of $12.00 (represents a 188.46% upside from SLDB’s last price of $4.16) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.

SLDB Price Target

The average price target for Solid Biosciences (SLDB) is $12.00 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $12.00. This represents a potential 188.46% upside from SLDB's last price of $4.16.

SLDB Analyst Ratings

Buy

According to 7 Wall Street analysts, Solid Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for SLDB stock is 0 'Strong Buy' (0.00%), 7 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Solid Biosciences Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jun 24, 2024	Joseph Schwartz	Leerink Partners	$12.00	$6.62	81.27%	188.46%
May 31, 2024	Biren Amin	Piper Sandler	$20.00	$7.64	161.78%	380.77%
May 16, 2024	Gena Wang	Barclays	$18.00	$9.69	85.76%	332.69%
Mar 13, 2024	Christopher Raymond	Raymond James	$20.00	$12.23	63.53%	380.77%

The latest Solid Biosciences stock forecast, released on Jun 24, 2024 by Joseph Schwartz from Leerink Partners, set a price target of $12.00, which represents a 81.27% increase from the stock price at the time of the forecast ($6.62), and a 188.46% increase from SLDB last price ($4.16).

Solid Biosciences Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	4
Avg Price Target	-	-	$17.50
Last Closing Price	$4.16	$4.16	$4.16
Upside/Downside	-100.00%	-100.00%	320.67%

In the current month, the average price target of Solid Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Solid Biosciences's last price of $4.16. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Aug 14, 2024	H.C. Wainwright	Buy	Buy	Hold
Jun 24, 2024	Leerink Partners		Outperform	Upgrade
Jun 21, 2024	Piper Sandler	Overweight	Overweight	Hold
May 16, 2024	Barclays	Overweight	Overweight	Hold
Mar 28, 2024	William Blair		Outperform	Initialise
Mar 13, 2024	Piper Sandler	Neutral	Overweight	Upgrade
Apr 28, 2022	Piper Sandler	Neutral	Neutral	Hold
Apr 28, 2022	SVB Leerink	Outperform	Outperform	Hold
Apr 28, 2022	Chardan Capital	Buy	Buy	Hold

Solid Biosciences's last stock rating was published by H.C. Wainwright on Aug 14, 2024. The company gave SLDB a "Buy" rating, the same as its previous rate.

Solid Biosciences Financial Forecast

Solid Biosciences Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$6.17M	$1.93M	$3.15M	$3.54M	$3.59M	$3.33M
Avg Forecast	-	-	-	-	-	-	-	$446.18K	$404.70K	$404.70K	$404.70K	$1.45M	$1.10M	$1.47M	$2.20M	$2.20M	$300.00K	$4.08M	$2.68M	$1.73M	$2.13M	$2.82M	$4.22M
High Forecast	-	-	-	-	-	-	-	$446.18K	$404.70K	$404.70K	$404.70K	$1.45M	$1.10M	$1.47M	$2.20M	$2.20M	$300.00K	$4.08M	$2.68M	$1.73M	$2.13M	$2.82M	$5.07M
Low Forecast	-	-	-	-	-	-	-	$446.18K	$404.70K	$404.70K	$404.70K	$1.45M	$1.10M	$1.47M	$2.20M	$2.20M	$300.00K	$4.08M	$2.68M	$1.73M	$2.13M	$2.82M	$3.38M
# Analysts	-	-	-	-	-	-	-	1	2	2	4	1	2	1	1	1	1	5	11	12	11	10	13
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.51%	0.72%	1.82%	1.66%	1.28%	0.79%

Solid Biosciences's average Quarter revenue forecast for Sep 22 based on 1 analysts is $300.00K, with a low forecast of $300.00K, and a high forecast of $300.00K. SLDB's average Quarter revenue forecast represents a -95.14% decrease compared to the company's last Quarter revenue of $6.17M (Jun 22).

Solid Biosciences EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
# Analysts	-	-	-	-	-	-	-	1	2	2	4	1	2	1	1	1	1	5	11	12	11	10	13
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	$-21.68M	$-23.11M	$-26.27M	$-30.95M	$-20.69M	$-21.62M	$-24.66M	$-17.85M	$-17.23M	$-17.98M	$-16.17M
Avg Forecast	-	-	-	-	-	-	-	$89.24K	$80.94K	$80.94K	$80.94K	$290.00K	$220.00K	$293.40K	$440.00K	$440.00K	$60.00K	$816.90K	$-19.15M	$346.45K	$426.96K	$563.28K	$-20.46M
High Forecast	-	-	-	-	-	-	-	$89.24K	$80.94K	$80.94K	$80.94K	$290.00K	$220.00K	$293.40K	$440.00K	$440.00K	$60.00K	$816.90K	$-15.32M	$346.45K	$426.96K	$563.28K	$-16.37M
Low Forecast	-	-	-	-	-	-	-	$89.24K	$80.94K	$80.94K	$80.94K	$290.00K	$220.00K	$293.40K	$440.00K	$440.00K	$60.00K	$816.90K	$-22.98M	$346.45K	$426.96K	$563.28K	$-24.55M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-98.54%	-78.78%	-59.70%	-70.35%	-344.91%	-26.47%	1.29%	-51.52%	-40.36%	-31.91%	0.79%

undefined analysts predict SLDB's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Solid Biosciences's previous annual EBITDA (undefined) of $NaN.

Solid Biosciences Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
# Analysts	-	-	-	-	-	-	-	1	2	2	4	1	2	1	1	1	1	5	11	12	11	10	13
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	$-20.34M	$-20.98M	$-24.63M	$-28.11M	$-19.69M	$-24.80M	$-25.28M	$-18.61M	$-17.98M	$-18.70M	$-16.90M
Avg Forecast	$-28.95M	$-27.53M	$-26.75M	$-27.45M	$-31.46M	$-30.60M	$-29.97M	$-31.02M	$-32.76M	$-27.69M	$-27.50M	$-26.50M	$-42.41M	$-49.00M	$-56.79M	$-66.79M	$-109.04M	$-133.04M	$-19.70M	$-122.80M	$-109.65M	$-106.65M	$-21.39M
High Forecast	$-28.95M	$-27.53M	$-26.75M	$-27.45M	$-31.46M	$-30.60M	$-29.97M	$-25.50M	$-25.71M	$-27.69M	$-27.50M	$-26.50M	$-22.67M	$-49.00M	$-56.79M	$-66.79M	$-109.04M	$-133.04M	$-15.76M	$-122.80M	$-109.65M	$-106.65M	$-17.11M
Low Forecast	$-28.95M	$-27.53M	$-26.75M	$-27.45M	$-31.46M	$-30.60M	$-29.97M	$-36.55M	$-37.73M	$-27.69M	$-27.50M	$-26.50M	$-56.69M	$-49.00M	$-56.79M	$-66.79M	$-109.04M	$-133.04M	$-23.64M	$-122.80M	$-109.65M	$-106.65M	$-25.67M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.48%	0.43%	0.43%	0.42%	0.18%	0.19%	1.28%	0.15%	0.16%	0.18%	0.79%

Solid Biosciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. SLDB's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Solid Biosciences SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
# Analysts	-	-	-	-	-	-	-	1	2	2	4	1	2	1	1	1	1	5	11	12	11	10	13
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	$6.22M	$6.41M	$7.13M	$7.40M	$7.13M	$6.85M	$7.35M	$7.21M	$7.14M	$6.77M	$6.01M
Avg Forecast	-	-	-	-	-	-	-	$764.64K	$693.56K	$693.56K	$693.56K	$2.48M	$1.89M	$2.51M	$3.77M	$3.77M	$514.13K	$7.00M	$4.59M	$2.97M	$3.66M	$4.83M	$7.23M
High Forecast	-	-	-	-	-	-	-	$764.64K	$693.56K	$693.56K	$693.56K	$2.48M	$1.89M	$2.51M	$3.77M	$3.77M	$514.13K	$7.00M	$4.59M	$2.97M	$3.66M	$4.83M	$8.68M
Low Forecast	-	-	-	-	-	-	-	$764.64K	$693.56K	$693.56K	$693.56K	$2.48M	$1.89M	$2.51M	$3.77M	$3.77M	$514.13K	$7.00M	$4.59M	$2.97M	$3.66M	$4.83M	$5.79M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	3.30%	2.55%	1.89%	1.96%	13.86%	0.98%	1.60%	2.43%	1.95%	1.40%	0.83%

Solid Biosciences's average Quarter SG&A projection for Mar 24 is $2.48M, based on 1 Wall Street analysts, with a range of $2.48M to $2.48M. The forecast indicates a -60.08% fall compared to SLDB last annual SG&A of $6.22M (Dec 23).

Solid Biosciences EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
# Analysts	-	-	-	-	-	-	-	1	2	2	4	1	2	1	1	1	1	5	11	12	11	10	13
EPS	-	-	-	-	-	-	-	-	-	-	-	-	$-1.00	$-1.05	$-1.25	$-1.44	$-2.61	$-3.30	$-3.37	$-2.49	$-2.40	$-2.50	$-2.84
Avg Forecast	$-0.70	$-0.66	$-0.65	$-0.66	$-0.76	$-0.74	$-0.72	$-0.75	$-0.79	$-0.67	$-0.66	$-0.64	$-1.02	$-1.18	$-1.37	$-1.61	$-2.66	$-3.25	$-2.91	$-3.00	$-2.68	$-2.61	$-4.86
High Forecast	$-0.70	$-0.66	$-0.65	$-0.66	$-0.76	$-0.74	$-0.72	$-0.62	$-0.62	$-0.67	$-0.66	$-0.64	$-0.55	$-1.18	$-1.37	$-1.61	$-2.66	$-3.25	$-2.91	$-3.00	$-2.68	$-2.61	$-4.86
Low Forecast	$-0.70	$-0.66	$-0.65	$-0.66	$-0.76	$-0.74	$-0.72	$-0.88	$-0.91	$-0.67	$-0.66	$-0.64	$-1.37	$-1.18	$-1.37	$-1.61	$-2.66	$-3.25	$-2.91	$-3.00	$-2.68	$-2.61	$-4.86
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.98%	0.89%	0.91%	0.89%	0.98%	1.02%	1.16%	0.83%	0.90%	0.96%	0.58%

According to undefined Wall Street analysts, Solid Biosciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to SLDB previous annual EPS of $NaN (undefined).

Solid Biosciences Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
PASG	Passage Bio	$0.67	$6.00	795.52%	Buy
BDTX	Black Diamond Therapeutics	$2.50	$20.00	700.00%	Buy
CABA	Cabaletta Bio	$2.75	$16.33	493.82%	Buy
MOLN	Molecular Partners	$5.25	$29.00	452.38%	Buy
CCCC	C4 Therapeutics	$4.05	$20.00	393.83%	Buy
ANEB	Anebulo Pharmaceuticals	$1.31	$6.00	358.02%	Buy
IPSC	Century Therapeutics	$1.17	$5.00	327.35%	Buy
PMVP	PMV Pharmaceuticals	$1.52	$6.00	294.74%	Buy
LRMR	Larimar Therapeutics	$4.32	$17.00	293.52%	Buy
ACRV	Acrivon Therapeutics	$7.21	$22.50	212.07%	Buy
CGEM	Cullinan Oncology	$11.49	$34.00	195.91%	Buy
SLDB	Solid Biosciences	$4.46	$12.00	169.06%	Buy
MLYS	Mineralys Therapeutics	$12.35	$30.00	142.91%	Buy
STOK	Stoke Therapeutics	$12.10	$26.50	119.01%	Buy
ALEC	Alector	$1.89	$4.00	111.64%	Buy
EWTX	Edgewise Therapeutics	$30.17	$46.25	53.30%	Buy
RVMD	Revolution Medicines	$45.16	$65.67	45.42%	Buy

SLDB Forecast FAQ

Is Solid Biosciences a good buy?

Yes, according to 7 Wall Street analysts, Solid Biosciences (SLDB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 100.00% of SLDB's total ratings.

What is SLDB's price target?

Solid Biosciences (SLDB) average price target is $12 with a range of $12 to $12, implying a 188.46% from its last price of $4.16. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Solid Biosciences stock go up soon?

According to Wall Street analysts' prediction for SLDB stock, the company can go up by 188.46% (from the last price of $4.16 to the average price target of $12), up by 188.46% based on the highest stock price target, and up by 188.46% based on the lowest stock price target.

Can Solid Biosciences stock reach $6?

SLDB's average twelve months analyst stock price target of $12 supports the claim that Solid Biosciences can reach $6 in the near future.

What are Solid Biosciences's analysts' financial forecasts?

Solid Biosciences's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $446.18K (high $446.18K, low $446.18K), average EBITDA is $89.24K (high $89.24K, low $89.24K), average net income is $-123M (high $-118M, low $-129M), average SG&A $764.64K (high $764.64K, low $764.64K), and average EPS is $-2.969 (high $-2.836, low $-3.103). SLDB's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-111M (high $-111M, low $-111M), average SG&A $0 (high $0, low $0), and average EPS is $-2.671 (high $-2.671, low $-2.671).

Did the SLDB's actual financial results beat the analysts' financial forecasts?

Based on Solid Biosciences's last annual report (Dec 2021), the company's revenue was $13.62M, beating the average analysts forecast of $10.9M by 24.90%. Apple's EBITDA was $-69.29M, beating the average prediction of $-19.123M by 262.33%. The company's net income was $-72.122M, missing the average estimation of $-360M by -79.99%. Apple's SG&A was $27.14M, beating the average forecast of $18.69M by 45.21%. Lastly, the company's EPS was $-10.13, missing the average prediction of $-13.144 by -22.93%. In terms of the last quarterly report (Jun 2022), Solid Biosciences's revenue was $6.17M, beating the average analysts' forecast of $4.08M by 51.03%. The company's EBITDA was $-21.62M, missing the average prediction of $816.9K by -2746.59%. Solid Biosciences's net income was $-24.802M, missing the average estimation of $-133M by -81.36%. The company's SG&A was $6.85M, missing the average forecast of $7M by -2.13%. Lastly, the company's EPS was $-3.3, beating the average prediction of $-3.25 by 1.54%